Provided by Tiger Trade Technology Pte. Ltd.

MAIA Biotechnology Inc.

1.40
+0.06004.48%
Post-market: 1.400.00000.00%19:53 EDT
Volume:907.36K
Turnover:1.26M
Market Cap:84.94M
PE:-2.30
High:1.42
Open:1.35
Low:1.34
Close:1.34
52wk High:3.19
52wk Low:0.8700
Shares:60.67M
Float Shares:55.61M
Volume Ratio:1.28
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6085
EPS(LYR):-0.7000
ROE:-218.68%
ROA:-92.10%
PB:4.11
PE(LYR):-2.00

Loading ...

MAIA says directors, officers hold 20.46% beneficial stake

Reuters
·
Jun 02

Maia Biotechnology Announces Open Market Purchases by CEO and Director

THOMSON REUTERS
·
Jun 02

Maia Biotechnology CEO Vlad Vitoc buys 72,700 common shares for $100,870.29

Reuters
·
Jun 02

Maia Biotechnology director Stan Smith acquires 75,000 shares valued at $100,200

Reuters
·
Jun 02

Maia Bio CSO Sergei Gryaznov acquires 2,000 common shares worth $2,690

Reuters
·
Jun 02

Maia Biotech presents Phase 3 THIO-104 trial design for ateganosine in checkpoint-resistant lung cancer at ASCO 2026

Reuters
·
Jun 01

Maia Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology

THOMSON REUTERS
·
Jun 01

MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology

GlobeNewswire
·
Jun 01

MAIA Biotechnology Shareholders Back Board and Auditor Appointments

TIPRANKS
·
May 22

Maia Biotechnology shareholders ratify Grant Thornton as 2026 auditor

Reuters
·
May 22

MAIA Biotechnology Ends ATM Stock Offering Agreement

TIPRANKS
·
May 15

Maia Biotechnology Inc - Sold 3.1 Mln Shares for Gross Proceeds of $5.7 Mln Under Sales Agreement - SEC Filing

THOMSON REUTERS
·
May 15

Maia Biotechnology Inc - to Terminate at the Market Offering Agreement Effective May 23, 2026 - SEC Filing

THOMSON REUTERS
·
May 15

MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) Estimate

Benzinga Earnings
·
May 11

Maia Biotechnology Q1 net loss widens 41% to $6.37 million

Reuters
·
May 11

Maia Biotech opens first US site for Phase 2 THIO-101 lung cancer trial

Reuters
·
Apr 16

MAIA Biotechnology secures funding for clinical trial of ateganosine

TIPRANKS
·
Apr 08

Maia Biotechnology says $33 million stock offering fully funds Phase 3 NSCLC trial

Reuters
·
Apr 08

MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy

GlobeNewswire
·
Apr 08

Maia Biotechnology announces annual shareholder meeting in virtual format

Reuters
·
Apr 07